Literature DB >> 908121

Bronchial reactivity to inhaled histamine: a method and clinical survey.

D W Cockcroft, D N Killian, J J Mellon, F E Hargreave.   

Abstract

An easy and safe dose-response histamine-inhalation test is described, to measure the level of non-specific bronchial reactivity. The test was performed in 307 subject. Non-specific bronchial reactivity was increased in 3% of presumed normal subjects, in 100% of active asthmatics and in 69% of asymptomatic asthmatics with previous symptoms only at times of exposure to clinically relevant allergens. It was also increased in 47% of patients with cough and no other chest symptoms, in 40% of patients with rhinitis and vague chest symptoms not by themselves diagnostic of asthma, and in 22% of patients with rhinitis and no chest symptoms. The patients with asthma were studied when their asthma was well controlled and when their minimum drug requirements had been established. The mean level of bronchial reactivity increased with increasing minimum drug requirements. The level of bronchial reactivity also showed a strong negative correlation with the forced expiratory volume in 1 sec (FEV1). Atopic subjects, with or without asthma, showed a significant positive correlation between the level of bronchial reactivity and atopic status as indicated by the number of positive allergy skin tests.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 908121     DOI: 10.1111/j.1365-2222.1977.tb01448.x

Source DB:  PubMed          Journal:  Clin Allergy        ISSN: 0009-9090


  269 in total

Review 1.  Methodology of bronchial responsiveness.

Authors:  S Chinn
Journal:  Thorax       Date:  1998-11       Impact factor: 9.139

Review 2.  Discriminating measures of bronchodilator drug efficacy and potency.

Authors:  H Buck; M Parry-Billings
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

3.  Association of CCR5Delta32 with reduced risk of childhood but not adult asthma.

Authors:  P Srivastava; P J Helms; D Stewart; M Main; G Russell
Journal:  Thorax       Date:  2003-03       Impact factor: 9.139

4.  Effect of inhaled prostaglandin D2 in normal and atopic subjects, and of pretreatment with leukotriene D4.

Authors:  S E Sampson; A P Sampson; J F Costello
Journal:  Thorax       Date:  1997-06       Impact factor: 9.139

5.  A major susceptibility gene for asthma maps to chromosome 14q24.

Authors:  Hakon Hakonarson; Unnur S Bjornsdottir; Eva Halapi; Snaebjorn Palsson; Elva Adalsteinsdottir; David Gislason; Gudmundur Finnbogason; Thorarinn Gislason; Kristleifur Kristjansson; Thor Arnason; Illugi Birkisson; Michael L Frigge; Augustine Kong; Jeffrey R Gulcher; Kari Stefansson
Journal:  Am J Hum Genet       Date:  2002-07-15       Impact factor: 11.025

6.  Bronchial responsiveness and lung function in infants with lower respiratory tract illness over the first six months of life.

Authors:  J R Clarke; A Reese; M Silverman
Journal:  Arch Dis Child       Date:  1992-12       Impact factor: 3.791

7.  Repeatability of methacholine challenge in asthmatic children measured by change in transcutaneous oxygen tension.

Authors:  S B Phagoo; N M Wilson; M Silverman
Journal:  Thorax       Date:  1992-10       Impact factor: 9.139

8.  Association between asthma-related phenotypes and the CC16 A38G polymorphism in an unselected population of young adult Danes.

Authors:  Pierre V Candelaria; Vibeke Backer; Ingrid A Laing; Celeste Porsbjerg; Steen Nepper-Christensen; Nick de Klerk; Jack Goldblatt; Peter N Le Souëf
Journal:  Immunogenetics       Date:  2005-03-03       Impact factor: 2.846

9.  Distribution of immunocompetent cells in the bronchial wall of clinically healthy subjects showing bronchial hyperresponsiveness.

Authors:  C Power; S Sreenan; B Hurson; C Burke; L W Poulter
Journal:  Thorax       Date:  1993-11       Impact factor: 9.139

10.  Occupational asthma due to soft corrosive soldering fluxes containing zinc chloride and ammonium chloride.

Authors:  D C Weir; A S Robertson; S Jones; P S Burge
Journal:  Thorax       Date:  1989-03       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.